Unifarco closes 2024 with revenues of 182.9 million euros (+10.5%)

Unifarco - a Belluno-based company that operates in the health and wellness sector in pharmacies with brands such as Ceramol, Biomalife and Dolomia - closed 2024 with a turnover of 182.9 million euros, up 10.5% compared to the previous year. Ebitda stood at 27.7 million euros.

All European markets are growing in double digits thanks to the export of their business model, adapted to the peculiarities of individual countries. In particular, the results of the Farmacisti Preparatori community brand and of the proprietary brands present abroad are highlighted, allowing growth in Spain by 21%, in Germany by 15.6%, in France - where the operational activity of the commercial branch Unifarco France was started in 2024 - and Belgium by 18.1% and in Austria by 17.1%.

Positive sign also for all the brands of the group: Farmacisti Preparatori, cosmetics and supplements signed by individual pharmacies, in 2024 recorded 111.9 million in consolidated turnover with a growth of 6.1% compared to the previous year; Ceramol - dermatological products and medical devices dedicated to the treatment of some specific skin dysfunctions - grew by 19.1%; Biomalife - the first line of specific food supplements to restore and maintain the well-being of the intestinal barrier - recorded +76.7%; Dolomia - skin care and make-up that use extracts of dolomitic nature to combat stress, pollution and skin aging - closed 2024 with a turnover in line with the previous year; MyCli - complete range of cosmeceuticals and nutritional supplements developed thanks to a strong expertise in the field of aesthetic medicine to stimulate and defend the skin's self-correction processes - closed the year with revenues of +24.3%; Keylife – a brand that offers low-carb, anti-inflammatory and metabolic control diet protocols – continues on the path of strong development started in previous years, closing the year with a 12% growth; Genage – a brand born from the collaboration with Metodo Ongaro Switzerland (now Swiss Longevity Solutions) and with international doctors, geneticists and researchers – records an increase of 28.1% compared to the previous year.

During the year, numerous activities in the Research and Development area continued, also through collaborations with prestigious research institutions, with the aim of always proposing cutting-edge, safe and effective solutions so that pharmacists can take care of people by providing personalized authoritative advice and offering products and services with high scientific value. In this regard, it should be noted that at a consolidated level, the overall investment in the scientific field exceeds 5 million euros, equal to 2.9% of sales revenues.

With over 6,500 client pharmacies in Europe and approximately 360 member pharmacists, Unifarco aims to grow further with investments that in 2024 reached 16 million euros.